D. Debieuvre

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 969 citations · Full text

Advanced Lung Disease, Medicine, Pathology +8

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011 · 573 citations

Elderly Patients, Medicine, Metronomic Therapy +7

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 451 citations · Full text

Ifct-1501 Maps2, Immune Checkpoint Inhibitor, Pleural Disease +5

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel et al. · The Lancet Oncology · 2011 · 264 citations

Vaccination, First-line Chemotherapy, Controlled Phase 2B +10

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Élisabeth Quoix, H. Léna, György Losonczy et al. · The Lancet Oncology · 2015 · 199 citations

First-line Chemotherapy, Phase 2B, Medicine +8